---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030460"
form_type: "8-K/A"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:25:27.165455+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen receives $1.5M from Fuji Pharma for exclusive PH80 negotiation in Japan

## Summary
- Received $1.5M non-refundable payment from Fuji Pharma for exclusive negotiation rights to license PH80 in Japan.
- PH80 is a non-systemic, hormone-free pherine nasal spray for acute treatment of moderate-to-severe hot flashes due to menopause.
- Purchase price credited against signing fee if definitive license agreement reached.
- Neither party obligated to enter definitive agreement; negotiations may be terminated after exclusive period.

## SEC filing metadata
- accession: 0001437749-23-030460
- form_type: 8-K/A
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923030460/0001437749-23-030460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923030460/vtgn20231106_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030460
- JSON: https://secwatch.observer/filing/0001437749-23-030460.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.